| Delfin George C Ibanez, MD | |
|
37 Court St, Freehold, NJ 07728-1709 | |
| (732) 780-7387 | |
| (732) 780-5257 |
| Full Name | Delfin George C Ibanez |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 47 Years |
| Location | 37 Court St, Freehold, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144292210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MA069662 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rutgers Health Behavioral Health | 2466346770 | 55 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.
Researchers at Washington State University have developed an implantable, biofuel-powered sensor that runs on sugar and can monitor a body's biological signals to detect, prevent and diagnose diseases.
A Medical University of South Carolina's (MUSC) Department of Family Medicine study concluded that people who began moderately consuming alcohol in middle-age experience a quick benefit of lower rates of cardiovascular disease morbidity with no change in mortality after four years.
Most autism spectrum disorders have a complex, multifactorial genetic component, making it difficult to find specific treatments. Rett syndrome is an exception.
› Verified 6 days ago
| Entity Name | Rutgers Health Behavioral Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891956298 PECOS PAC ID: 2466346770 Enrollment ID: O20040419001021 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.
Researchers at Washington State University have developed an implantable, biofuel-powered sensor that runs on sugar and can monitor a body's biological signals to detect, prevent and diagnose diseases.
A Medical University of South Carolina's (MUSC) Department of Family Medicine study concluded that people who began moderately consuming alcohol in middle-age experience a quick benefit of lower rates of cardiovascular disease morbidity with no change in mortality after four years.
Most autism spectrum disorders have a complex, multifactorial genetic component, making it difficult to find specific treatments. Rett syndrome is an exception.
› Verified 6 days ago
| Entity Name | Valeo Behavioral Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851677033 PECOS PAC ID: 0042487233 Enrollment ID: O20120111000123 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.
Researchers at Washington State University have developed an implantable, biofuel-powered sensor that runs on sugar and can monitor a body's biological signals to detect, prevent and diagnose diseases.
A Medical University of South Carolina's (MUSC) Department of Family Medicine study concluded that people who began moderately consuming alcohol in middle-age experience a quick benefit of lower rates of cardiovascular disease morbidity with no change in mortality after four years.
Most autism spectrum disorders have a complex, multifactorial genetic component, making it difficult to find specific treatments. Rett syndrome is an exception.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Delfin George C Ibanez, MD 37 Court St, Freehold, NJ 07728-1709 Ph: (732) 780-7387 | Delfin George C Ibanez, MD 37 Court St, Freehold, NJ 07728-1709 Ph: (732) 780-7387 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
There is good news for patients who regularly take drugs for conditions such as high blood pressure and diabetes. The prices of these medicines in Australia could be reduced sharply from next year.
Researchers at Washington State University have developed an implantable, biofuel-powered sensor that runs on sugar and can monitor a body's biological signals to detect, prevent and diagnose diseases.
A Medical University of South Carolina's (MUSC) Department of Family Medicine study concluded that people who began moderately consuming alcohol in middle-age experience a quick benefit of lower rates of cardiovascular disease morbidity with no change in mortality after four years.
Most autism spectrum disorders have a complex, multifactorial genetic component, making it difficult to find specific treatments. Rett syndrome is an exception.
› Verified 6 days ago
Shengxi Lin, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 37 Court St, Freehold, NJ 07728 Phone: 732-780-7387 | |
Moustafa Shafey, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 901 W Main St, Freehold, NJ 07728 Phone: 732-431-2000 | |
Caren G. Marks, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 901 W Main St Ste 364, Freehold, NJ 07728 Phone: 732-729-4325 Fax: 732-761-8084 | |
David J Frank, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 Iron Bridge Rd Ste 3, Freehold, NJ 07728 Phone: 732-462-7030 Fax: 732-308-3562 | |
Dr. Terence Mcalarney, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 901 W Main St, Medical Arts Building Suite 101, Freehold, NJ 07728 Phone: 735-625-8460 Fax: 732-863-9382 | |
Dr. Chandrika Nadipuram, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 14 Autumn Ln, Freehold, NJ 07728 Phone: 848-863-6621 |